二次电切联合吡柔比星即刻灌注治疗非肌层浸润性膀胱癌临床疗效观察

doi:10.19558/j.cnki.10-1020/r.2018.01.014

摘要
图/表
参考文献
相关文章 (10)

全文: PDF (770 KB) RICH HTML
输出: BibTeX | EndNote (RIS)

摘要 目的:探讨二次电切联合吡柔比星即刻灌注治疗非肌层浸润性膀胱癌临床治疗效果。方法:回顾2010年1月~2014年5月诊断为非肌层浸润性膀胱癌共63 例患者,分为对照组和观察组,其中拒绝行二次TURBT患者28例作为对照组,行二次TURBT治疗患者35例作为观察组。所有病例均于术后即刻行吡柔比星灌注治疗。对比两组患者6、12、18、24个月肿瘤复发率及进展率。结果:一次电切患者6、12、18、24个月肿瘤复发率、进展率分别为:10.7%、0;17.9%、3.6%;28.6%、10.7%;46.4%、21.4%。二次电切患者6、12、18、24个月肿瘤复发率及进展率分别为2.9%、0;2.9%、0;8.6%、2.9%;14.3%,5.7%,差异有统计学意义(均P<0.01)。结论:TURBT术后即刻行膀胱灌注化疗,能显著降低非肌层浸性膀胱癌的复发率,二次电切对于彻底清除非肌层浸润性膀胱残余肿瘤、减少其复发率及进展率有十分重要的意义,有助于临床医生选择正确的后续治疗方案和提高患者的生存率。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	白大应
	刘杰
	王云杰
	李柱仕
	张忠军

关键词 ：二次电切, 非肌层浸润性膀胱癌, 肿瘤复发, 局部, 即刻灌注, 吡柔比星

Abstract：Objective: To evaluate the clinical efficacy of immediate intravesical instillation of second resection combined with pirarubicin in the treatment of non-muscular invasive bladder carcinoma (NMIBC). Methods: Sixty-three cases of NMIBC from Jan. 2010 to May 2014 were reviewed. The patients who received second resection of transurethral resection of bladder tumor (TURBT) served as treatment group (35 cases), and the rest 28 cases given only one resection as control group. All of the patients were treated with immediate intravesical instillation with pirarubicin. Recurrence and progression between the two groups were observed at 6th, 12th, 18th and 24th month. Results: At 6th, 12th, 18th and 24th month, the recurrence rate and the progression rate had statistically significant difference between treatment group and control group (P<0.01) (for control group: 10.7% and 0, 17.9% and 3.6%, 28.6% and 10.7%, and 46.4% and 21.4% respectively; for treatment group: 2.9% and 0, 2.9% and 0, 8.6% and 2.9%, and 14.3% and 5.7% respectively). Conclusions: Immediate intravesical instillation of pirarubicin after TURBT can significantly can significantly reduce the relapse of NMIBC. Second resection was effective for removing the remnant tumors of NMIBC and also helped clinicians choose the right treatment strategies and improve the survival of patients with NMIBC.

Key words： second resection non-muscle invasive bladder urothelial carcinoma neoplasm recurrence local immediate intravesical instillation pirarubicin

收稿日期: 2017-04-25

ZTFLH:

R737.14

通讯作者: 白大应,baidaying@163.com

引用本文:

白大应, 刘杰, 王云杰, 李柱仕, 张忠军. 二次电切联合吡柔比星即刻灌注治疗非肌层浸润性膀胱癌临床疗效观察[J]. 微创泌尿外科杂志, 2018, 7(1): 61-64.
Bai Daying, Liu Jie, Wang Yunjie, Li Zhushi, Zhang Zhongjun. Clinical effectiveness of immediate intravesical instillation of second resection combined with pirarubicin in the treatment of non-muscular invasive bladder urothelial carcinoma. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2018, 7(1): 61-64.

链接本文:

http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/abstract/abstract1343.shtml 或 http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/Y2018/V7/I1/61

[1] 温登瑰,单保恩,张思维,等.2003-2007年中国肿瘤登记地区膀胱癌的发病与死亡分析.肿瘤,2012,32(4):256-262.
[2] 程波,张海芳,黄连饴.非肌层浸润性膀胱癌术后再电切的临床分析.中华老年医学杂志,2014,33(2):183-185.
[3] 胥金斌,徐建林,邵建中.经尿道二次电切治疗非肌层浸润性膀胱肿瘤的临床研究.临床外科杂志,2013,21(2):103-104.
[4] 黄洁夫. 非肌层浸润性膀胱癌复发、进展预后的研究进展.中华腔镜泌尿外科杂志(电子版),2013,7(4):315-317.
[5] Stein JP.Indications for early cystectomy. Urology, 2003,62(4):591-595.
[6] 顾方六. 尿路上皮肿瘤的诊断与治疗.吴阶平泌尿外科学.济南:山东科学技术出版社,2004:959-980.
[7] Borden LS Jr, Clark PE, Hall MC.Bladder cancer. Curt Opin Oncol, 2005,17(3):275-280.
[8] Babjuk M, Burger M, Zigeuner R, et al.EAU guidelines on non-muscle, invasive urothelial carcinoma of the bladder: update 2013. Eur Urol, 2013,64(4):639-653.
[9] 那彦群,叶章群,孙颖浩.2014版中国泌尿外科疾病诊断治疗指南.北京:人民卫生出版社,2013:20-60.
[10] 陶勇,彭玉兰,余刚.二次电切在非肌层浸润性膀胱癌的临床价值.中华腔镜泌尿外科杂志(电子版),2014,8(4):274-277.
[11] 李琦,许锋,张天标,等.二次电切对T1G3期膀胱癌复发的影响.中国现代医生,2013,51(21):142-143.
[12] 任维果,孙晓文,李维国,等.二次电切在高危非肌层浸润膀胱癌治疗中的作用.现代泌尿外科杂志,2015,20(3):163-164.
[13] 那彦群,孙光.中国泌尿外科疾病诊断治疗指南.北京:人民卫生出版社,2009:23-38.
[14] Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage TaT1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol, 2004,171(6 Pt 1):2186-2190.
[15] Li NC, Ye ZQ, Na YQ.Efficacy of immediate instillation combined with regular instillations of pirarubicin for Ta and T1 transitional cell bladder cancer after transurethral resection: a prospective, randomized, multicenter study. Chin Med J (Engl), 2013,126(15):2805-2809.